1 | markedly | 4,376 |
2 | substantially | 4,048 |
3 | greatly | 2,295 |
4 | considerably | 2,168 |
5 | dramatically | 1,521 |
6 | obviously | 1,387 |
7 | transiently | 534 |
8 | dose-dependently | 504 |
9 | drastically | 287 |
10 | profoundly | 278 |
11 | distinctly | 232 |
12 | appreciably | 184 |
13 | insignificantly | 178 |
14 | noticeably | 133 |
15 | radically | 126 |
16 | vastly | 67 |
17 | tremendously | 45 |
18 | enormously | 43 |
19 | substantively | 42 |
20 | measurably | 27 |
21 | decisively | 23 |
22 | conspicuously | 21 |
23 | detectably | 11 |
24 | significatively | 11 |
25 | authentically | 9 |
26 | compensatorily | 7 |
27 | many-fold | 6 |
28 | signficantly | 5 |
29 | dose-relatedly | 3 |
30 | markably | 3 |
31 | .aprotinin | 2 |
32 | 11.3-fold | 2 |
33 | 250-fold | 2 |
34 | cost/remuneration | 2 |
35 | cyclophosphamide-doxorubicin-vincristine | 2 |
36 | half-maximally | 2 |
37 | hypersomnolescence | 2 |
38 | obl-b | 2 |
39 | perceptibly | 2 |
40 | psr2 | 2 |
41 | sizeably | 2 |
42 | tofacitinib-associated | 2 |
43 | ~2.5-fold | 2 |
44 | .bisphosphonates | 1 |
45 | .pacemakers | 1 |
46 | 1808-fold | 1 |
47 | 6-phenyl-4-hydroxypyridazin-3 | 1 |
48 | aliskiren+valsartan | 1 |
49 | diary-an | 1 |
50 | efficacy-hopefully | 1 |
51 | ences | 1 |
52 | endomorphy | 1 |
53 | grade-for-grade | 1 |
54 | harmlessly | 1 |
55 | i-2494 | 1 |
56 | improved/much | 1 |
57 | indole-3-propionate | 1 |
58 | ipth-level | 1 |
59 | kf180 | 1 |
60 | macrozooplankton | 1 |
61 | mstn1 | 1 |
62 | offten | 1 |
63 | peaks/sec | 1 |
64 | percentually | 1 |
65 | recently-is | 1 |
66 | review.thiazides | 1 |
67 | ribofuranoside | 1 |
68 | sex-specifically | 1 |
69 | sharpy | 1 |
70 | species-specifically | 1 |
71 | strength-dependently | 1 |
72 | ~95-fold | 1 |
73 | γ-ntp | 1 |
74 | ⅶ | 1 |
75 | ∼7°c | 1 |
1 | .aprotinin | 2 |
2 | .bisphosphonates | 1 |
3 | .pacemakers | 1 |
4 | 11.3-fold | 2 |
5 | 1808-fold | 1 |
6 | 250-fold | 2 |
7 | 6-phenyl-4-hydroxypyridazin-3 | 1 |
8 | aliskiren+valsartan | 1 |
9 | appreciably | 184 |
10 | authentically | 9 |
11 | compensatorily | 7 |
12 | considerably | 2,168 |
13 | conspicuously | 21 |
14 | cost/remuneration | 2 |
15 | cyclophosphamide-doxorubicin-vincristine | 2 |
16 | decisively | 23 |
17 | detectably | 11 |
18 | diary-an | 1 |
19 | distinctly | 232 |
20 | dose-dependently | 504 |
21 | dose-relatedly | 3 |
22 | dramatically | 1,521 |
23 | drastically | 287 |
24 | efficacy-hopefully | 1 |
25 | ences | 1 |
26 | endomorphy | 1 |
27 | enormously | 43 |
28 | grade-for-grade | 1 |
29 | greatly | 2,295 |
30 | half-maximally | 2 |
31 | harmlessly | 1 |
32 | hypersomnolescence | 2 |
33 | i-2494 | 1 |
34 | improved/much | 1 |
35 | indole-3-propionate | 1 |
36 | insignificantly | 178 |
37 | ipth-level | 1 |
38 | kf180 | 1 |
39 | macrozooplankton | 1 |
40 | many-fold | 6 |
41 | markably | 3 |
42 | markedly | 4,376 |
43 | measurably | 27 |
44 | mstn1 | 1 |
45 | noticeably | 133 |
46 | obl-b | 2 |
47 | obviously | 1,387 |
48 | offten | 1 |
49 | peaks/sec | 1 |
50 | percentually | 1 |
51 | perceptibly | 2 |
52 | profoundly | 278 |
53 | psr2 | 2 |
54 | radically | 126 |
55 | recently-is | 1 |
56 | review.thiazides | 1 |
57 | ribofuranoside | 1 |
58 | sex-specifically | 1 |
59 | sharpy | 1 |
60 | signficantly | 5 |
61 | significatively | 11 |
62 | sizeably | 2 |
63 | species-specifically | 1 |
64 | strength-dependently | 1 |
65 | substantially | 4,048 |
66 | substantively | 42 |
67 | tofacitinib-associated | 2 |
68 | transiently | 534 |
69 | tremendously | 45 |
70 | vastly | 67 |
71 | ~2.5-fold | 2 |
72 | ~95-fold | 1 |
73 | γ-ntp | 1 |
74 | ⅶ | 1 |
75 | ∼7°c | 1 |
1 | kf180 | 1 |
2 | mstn1 | 1 |
3 | psr2 | 2 |
4 | 6-phenyl-4-hydroxypyridazin-3 | 1 |
5 | i-2494 | 1 |
6 | obl-b | 2 |
7 | peaks/sec | 1 |
8 | ∼7°c | 1 |
9 | tofacitinib-associated | 2 |
10 | 250-fold | 2 |
11 | 11.3-fold | 2 |
12 | ~2.5-fold | 2 |
13 | ~95-fold | 1 |
14 | 1808-fold | 1 |
15 | many-fold | 6 |
16 | hypersomnolescence | 2 |
17 | grade-for-grade | 1 |
18 | ribofuranoside | 1 |
19 | cyclophosphamide-doxorubicin-vincristine | 2 |
20 | indole-3-propionate | 1 |
21 | improved/much | 1 |
22 | ipth-level | 1 |
23 | diary-an | 1 |
24 | aliskiren+valsartan | 1 |
25 | offten | 1 |
26 | .aprotinin | 2 |
27 | cost/remuneration | 2 |
28 | macrozooplankton | 1 |
29 | γ-ntp | 1 |
30 | ences | 1 |
31 | review.thiazides | 1 |
32 | .bisphosphonates | 1 |
33 | recently-is | 1 |
34 | .pacemakers | 1 |
35 | endomorphy | 1 |
36 | noticeably | 133 |
37 | sizeably | 2 |
38 | appreciably | 184 |
39 | markably | 3 |
40 | considerably | 2,168 |
41 | measurably | 27 |
42 | detectably | 11 |
43 | perceptibly | 2 |
44 | markedly | 4,376 |
45 | dose-relatedly | 3 |
46 | profoundly | 278 |
47 | decisively | 23 |
48 | significatively | 11 |
49 | substantively | 42 |
50 | compensatorily | 7 |
51 | radically | 126 |
52 | species-specifically | 1 |
53 | sex-specifically | 1 |
54 | dramatically | 1,521 |
55 | authentically | 9 |
56 | drastically | 287 |
57 | substantially | 4,048 |
58 | half-maximally | 2 |
59 | percentually | 1 |
60 | efficacy-hopefully | 1 |
61 | harmlessly | 1 |
62 | tremendously | 45 |
63 | obviously | 1,387 |
64 | enormously | 43 |
65 | conspicuously | 21 |
66 | greatly | 2,295 |
67 | distinctly | 232 |
68 | insignificantly | 178 |
69 | signficantly | 5 |
70 | dose-dependently | 504 |
71 | strength-dependently | 1 |
72 | transiently | 534 |
73 | vastly | 67 |
74 | sharpy | 1 |
75 | ⅶ | 1 |